Fortrea Holdings (FTRE) Other Non-Current Liabilities (2022 - 2026)
Fortrea Holdings (FTRE) posted Other Non-Current Liabilities of $37.8 million for Q1 2026, down 3.82% on a QoQ basis from $39.3 million in Q4 2025, and up 4.13% year-over-year from $36.3 million in Q1 2025.
Fortrea Holdings (FTRE) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $37.8 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 4.13% year-over-year to $37.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 4.13% YoY) and the FY2025 annual result came in at $39.3 million, up 11.33% from the prior year.
- Other Non-Current Liabilities was $37.8 million for Q1 2026 at Fortrea Holdings, down from $39.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $39.3 million in Q4 2025 and bottomed at $21.7 million in Q4 2022.
- A 5-year average of $34.2 million and a median of $36.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities soared 47.93% — and 2024, when it decreased 20.0%.
- Fortrea Holdings' Other Non-Current Liabilities stood at $21.7 million in 2022, then surged by 47.93% to $32.1 million in 2023, then climbed by 9.97% to $35.3 million in 2024, then climbed by 11.33% to $39.3 million in 2025, then fell by 3.82% to $37.8 million in 2026.
- Business Quant data shows FTRE's Other Non-Current Liabilities at $37.8 million in Q1 2026, $39.3 million in Q4 2025, and $36.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Fortrea Holdings | 1.79 Bn | 1.64 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.80 Mn |
| Dec 31, 2025 | 39.30 Mn |
| Sep 30, 2025 | 36.40 Mn |
| Jun 30, 2025 | 37.00 Mn |
| Mar 31, 2025 | 36.30 Mn |
| Dec 31, 2024 | 35.30 Mn |
| Sep 30, 2024 | 37.60 Mn |
| Jun 30, 2024 | 29.60 Mn |
| Mar 31, 2024 | 28.90 Mn |
| Dec 31, 2023 | 32.10 Mn |
| Sep 30, 2023 | 35.70 Mn |
| Jun 30, 2023 | 37.00 Mn |
| Dec 31, 2022 | 21.70 Mn |